Merck Protease Inhibitor Impresses At EASL, Anadys Suffers Rash Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The second-generation protease inhibitors for hepatitis C could have a tough time competing with the lead agents in the class, Vertex's telaprevir and Schering-Plough's boceprevir - as data presented at the European Association for the Study of the Liver's recent meeting reveals safety problems with some of the products in earlier stage development